John W Mccullough

US Patent:

6342496, Jan 29, 2002

Filed:

Feb 22, 2000

Appl. No.:

09/510241

Inventors:

Thomas P. Jerussi - Framingham MA
John R. McCullough - Hudson MA
Chrisantha H. Senanayake - Shrewsbury MA
Qun K. Fang - Wellesley MA

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K 31535

US Classification:

5142312, 514649, 514653

Abstract:

Methods are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, cerebral function disorders, cigarette smoking, and incontinence.

US Patent:

6455530, Sep 24, 2002

Filed:

Sep 18, 2000

Appl. No.:

09/663992

Inventors:

Patrick Koch - Marlborough MA
John R. McCullough - Worcester MA
Chris H. Senanayake - Shrewsbury MA
Gerald J. Tanoury - Marlborough MA
Yaping Hong - Framingham MA

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K 31496

US Classification:

51425407, 514 85, 544337, 544366

Abstract:

A method of preparation of optically pure isomers of hydroxyitraconazole, in particular the two cis dioxolane diastereomers of the sec-butyl (S,S)-isomer, and to phosphate and sulfate derivatives thereof is disclosed. Pharmaceutical compositions containing these compounds and to their use for the treatment of fungal infection are also disclosed.

US Patent:

6458374, Oct 1, 2002

Filed:

Jan 28, 1999

Appl. No.:

09/238984

Inventors:

John R. McCullough - Hudson MA
Paul D. Rubin - Sudbury MA

Assignee:

Sepracor, Inc. - Marlborough MA

International Classification:

A61F 202

US Classification:

424423, 443451, 443464

Abstract:

Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

US Patent:

6495605, Dec 17, 2002

Filed:

Mar 13, 2001

Appl. No.:

09/803956

Inventors:

John R. McCullough - Hudson MA
Paul D. Rubin - Sudbury MA

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A01N 3302

US Classification:

514646

Abstract:

Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

US Patent:

6632827, Oct 14, 2003

Filed:

Mar 16, 2001

Appl. No.:

09/809165

Inventors:

John R. McCullough - Hudson MA
Thomas P. Jerussi - Framingham MA

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K 31445

US Classification:

514327

Abstract:

Compositions and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

US Patent:

20020052340, May 2, 2002

Filed:

Nov 16, 2001

Appl. No.:

09/987930

Inventors:

Thomas Jerussi - Farmingham MA, US
John McCullough - Hudson MA, US
Chrisantha Senanayake - Shrewsbury MA, US
Qun Fang - Wellesley MA, US

International Classification:

A61K031/135
A61K031/724

US Classification:

514/058000, 514/649000

Abstract:

Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, erectile dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. The invention further discloses methods of making optically pure bupropion metabolites.

US Patent:

20030096873, May 22, 2003

Filed:

Oct 23, 2002

Appl. No.:

10/277905

Inventors:

John McCullough - Hudson MA, US
Paul Rubin - Sudbury MA, US

Assignee:

Sepracor Inc.

International Classification:

A61K031/137

US Classification:

514/649000

Abstract:

Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

US Patent:

20040044039, Mar 4, 2004

Filed:

Sep 3, 2003

Appl. No.:

10/653072

Inventors:

John McCullough - Hudson MA, US
Thomas Jerussi - Framingham MA, US

Assignee:

Sepracor Inc. - Marlborough MA

International Classification:

A61K031/445

US Classification:

514/317000

Abstract:

Compositons employing and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.